BriaCell Therapeutics Corp. to Clarify Record Date
02 October 2019 - 9:00AM
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage
biotechnology company specializing in targeted immunotherapy for
advanced breast cancer, announced on August 23, 2019 that it will
hold a special meeting of shareholders on October 22, 2019 (the
"
Meeting").
The Company would like to clarify that September
18, 2019 was the record date for determining shareholders of the
Company entitled to receive notice of, and to vote at, the Meeting
being held on October 22, 2019 in Toronto. The Company
inadvertently advertised September 20, 2019 as the record date in
its management information circular, dated September 23, 2019, for
the upcoming Meeting. Please refer to the Notice of Meeting and
Record Date posted under the Company's SEDAR profile on August 23,
2019 for a complete list of important dates related to the
Meeting.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and safe approaches for
the management of cancer.
BriaCell is currently conducting a Phase I/IIa
clinical trial of Bria-IMT™, BriaCell’s lead candidate, in a
Combination Study with immune checkpoint inhibitors such as
pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc.
(NYSE: MRK)]. The Combination Study is listed in ClinicalTrials.gov
as NCT03328026.
BriaCell also has a non-exclusive clinical trial
collaboration with Incyte Corporation to evaluate the effects of
combinations of novel clinical candidates. Under the agreement,
Incyte and BriaCell will be evaluating novel combinations of
compounds from Incyte’s development portfolio with Bria-IMT™ in
advanced breast cancer patients.
BriaCell is developing Bria-OTS™, an
off-the-shelf personalized immunotherapy, for advanced breast
cancer. Bria-OTS™ immunotherapy treatments are personalized to
match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 99 percent of the
patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while
eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2024 to May 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From May 2023 to May 2024